Phase 3 trial shows efficacy of new antibiotic against gonorrhoea
One oral dose of zoliflodacin—a new antibiotic—is as effective as the current treatment for uncomplicated urogenital gonorrhoea, according to the results of a phase 3 clinical trial published in The Lancet. In some parts of the world, the bacteria that cause gonorrhoea have developed resistance to the current treatment, which combines an injection of ceftriaxone and an oral dose of azithromycin. Zoliflodacin could be an alternative to this treatment, concludes the study, which included 900 people from five countries.
0